



## Article

# In Vitro Immune Response of Mononuclear Cells to Multidrug-Resistant *Escherichia coli*

Berta Cuyàs<sup>1,2,3</sup> , Elisabet Cantó<sup>4</sup>, Elisabet Sanchez-Ardid<sup>1,3</sup>, Elisenda Miró<sup>5,6</sup> , Edilmar Alvarado-Tapias<sup>1,2,3</sup>, Eva Román<sup>1,2,3</sup> , Maria Poca<sup>1,2,3</sup> , Ferran Navarro<sup>5,6</sup> , Andreu Ferrero-Gregori<sup>4</sup> , Maria Àngels Escorsell<sup>1,2,3</sup> , Silvia Vidal<sup>4</sup> and German Soriano<sup>1,2,3,\*</sup>

<sup>1</sup> Department of Gastroenterology, Hospital de la Santa Creu i Sant Pau, C/Mas Casanovas 90, 08041 Barcelona, Spain; bcuyas@santpau.cat (B.C.)

<sup>2</sup> Department of Medicine, Universitat Autònoma de Barcelona, 08023 Barcelona, Spain

<sup>3</sup> Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, 28029 Madrid, Spain

<sup>4</sup> Inflammatory Diseases Department, Institut de Recerca Sant Pau (IR Sant Pau), 08041 Barcelona, Spain

<sup>5</sup> Department of Microbiology, Hospital de la Santa Creu i Sant Pau, C/Mas Casanovas 90, 08041 Barcelona, Spain

<sup>6</sup> Department of Genetics and Microbiology, Institut de Recerca Sant Pau (IR Sant Pau), Universitat Autònoma de Barcelona, 08041 Barcelona, Spain

\* Correspondence: gsoriano@santpau.cat; Tel.: +34-609732644

**Abstract:** Infections caused by multidrug-resistant organisms (MDRO) are linked to poor outcomes, particularly in patients with cirrhosis. The underlying mechanisms are not fully understood and may involve a different immune response against MDRO. This study aimed to compare the in vitro immune response between multidrug-resistant (MDR) *Escherichia coli* and antibiotic-susceptible *E. coli* strains. Surface protein extract and DNA extract were obtained from MDR *E. coli* (n = 6) and antibiotic-susceptible *E. coli* (n = 6) strains isolated from infected patients with cirrhosis. The extracts were used to stimulate in vitro peripheral blood mononuclear cells from healthy donors. After 48 h, cytokine levels (IFN- $\gamma$ , IL-1 $\beta$ , IL-10, IL-12p70, MCP-1, IL-8, IL-6, MIP-1 $\alpha$ , and MIP-1 $\beta$ ) were measured. We observed no significant differences in cytokine production between MDR and susceptible strains. However, we identified notable interindividual variability in cytokine production for most of the cytokines studied. Only IFN- $\gamma$  and IL-6 in surface extract and MCP-1 in DNA extract showed similar levels across all donors. We conclude that the cytokine profiles induced by MDR *E. coli* in vitro were similar to those in susceptible strains. These findings suggest that the poor prognosis associated with MDR *E. coli* infections is not due to a differential immune response but rather to other factors.

**Keywords:** resistance; cirrhosis; immune response; MDRO; *Escherichia coli*; cytokines



Academic Editor: Zhihui Cheng

Received: 14 April 2025

Revised: 16 May 2025

Accepted: 18 May 2025

Published: 20 May 2025

**Citation:** Cuyàs, B.; Cantó, E.; Sanchez-Ardid, E.; Miró, E.; Alvarado-Tapias, E.; Román, E.; Poca, M.; Navarro, F.; Ferrero-Gregori, A.; Escorsell, M.À.; et al. In Vitro Immune Response of Mononuclear Cells to Multidrug-Resistant *Escherichia coli*. *Microorganisms* **2025**, *13*, 1164. <https://doi.org/10.3390/microorganisms13051164>

**Copyright:** © 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

## 1. Introduction

Antimicrobial resistance is one of the most critical threats to global public health. It is directly responsible for over one million deaths annually worldwide, with the total number expected to exceed 29 million over the next 25 years [1]. This problem is particularly relevant in vulnerable populations, such as patients with cirrhosis. These patients present a spectrum of immune alterations known as cirrhosis-associated immune dysfunction (CAID). CAID is characterized by immune deficiencies and a proinflammatory state. The immune deficiencies, together with microbiome dysbiosis, altered intestinal permeability, and gut bacterial translocation leads to an increase in the incidence of infections [2,3]. As

a consequence, infections are a major cause of morbidity and mortality in patients with cirrhosis [4]. In recent years, the prevalence of multidrug-resistant organisms (MDRO) has increased notably in patients with cirrhosis as the result of frequent antibiotic exposure, recurrent hospitalizations, and invasive procedures [5]. Infections caused by MDRO now occur in approximately one-third of culture-positive bacterial infections in patients with cirrhosis worldwide, with significant geographical variation [6]. Multidrug resistance is increasing particularly among Gram-negative bacteria, with *Escherichia coli*, the most prevalent infectious agent in cirrhosis, being a leading contributor [6]. *E. coli* resistance is frequently driven by the acquisition of extended-spectrum beta-lactamases (ESBL) [7].

Infections caused by MDRO in cirrhosis are associated with poorer clinical outcomes, including lower rates of infection resolution, increased mortality and a higher incidence of septic shock and organ failure [6,8,9]. This organ failure often manifests as acute-on-chronic liver failure (ACLF), a severe condition that is unique to cirrhosis [10]. A delay in adequate antibiotic treatment seems to be the main reason for the poorer outcomes in patients with infections caused by MDRO [6,9,11]. However, it remains unclear whether other factors, such as a different inflammatory response against MDRO, could also contribute to the poor prognosis. This question is especially relevant in patients with cirrhosis. These patients are not only predisposed to infections because of their immune deficiencies. CAID also encompasses high-grade and low-grade systemic inflammation, together with an increased production of proinflammatory cytokines [2]. Among these cytokines, IL-6 and IL-8 are of particular relevance because their excessive production has been related to a worse prognosis and ACLF development in patients with cirrhosis [12,13].

Data regarding the in vitro inflammatory response against MDRO are scarce and contradictory. While some authors have reported an increased production of proinflammatory cytokines induced by multidrug-resistant (MDR) *E. coli* in comparison with susceptible strains [14], other studies have found a lower production [15]. It is relevant to elucidate whether the immune response elicited by MDRO is different from that against susceptible strains. This difference could have significant therapeutic implications in the future, not only in high-risk groups such as patients with cirrhosis but also in the general population.

We aimed to determine whether the in vitro immune response differs between MDR *E. coli* and susceptible *E. coli* strains isolated from infected patients with cirrhosis.

## 2. Materials and Methods

### 2.1. Bacterial Isolates and Growth Conditions

Twelve *E. coli* isolates from infected patients with cirrhosis were randomly selected and used for the experiments: six from ascitic fluid in the context of a spontaneous bacterial peritonitis (SBP) and six from blood in the context of bacteremia. SBP was defined as a bacterial infection of ascitic fluid without any intra-abdominal surgically treatable source of infection, while bacteremia refers to a bloodstream infection according to current guidelines [16].

Identification of *E. coli* isolates was initially suspected based on colony morphology and growth on chromogenic agar (CPS agar; bioMérieux, Marcy-l'Étoile, France). Species confirmation was subsequently performed using MALDI-TOF mass spectrometry (Bruker Daltonics GmbH & Co., KG, Bremen, Germany).

Antimicrobial susceptibility testing was performed using the disk diffusion method in accordance with the guidelines established by the European Committee on Antimicrobial Susceptibility Testing (EUCAST). Mueller–Hinton agar was used for all assays, and incubation was carried out at  $35 \pm 1$  °C for 16–20 h in aerobic conditions. The results were interpreted following EUCAST breakpoints applicable to the years of the study (EUCAST v8.1, 2018; EUCAST v9.0, 2019; and EUCAST v10.0, 2020) [17–19].

Isolates showing resistance or reduced susceptibility to third-generation cephalosporins (e.g., cefotaxime, ceftazidime, ceftriaxone) were simultaneously screened for potential ESBL production by observing synergy between cephalosporin disks and an amoxicillin-clavulanic acid (20/10) disk. Ceftazidime (30 µg), cefotaxime (30 µg) and cefepime (30 µg) disks were placed 20–30 mm from the central clavulanate disk on Mueller–Hinton agar plates inoculated with bacterial suspensions adjusted to 0.5 McFarland turbidity. Enhancement of the inhibition zone between the clavulanate disk and any of the cephalosporin disks was interpreted as indicative of ESBL activity [20]. Quality control was performed throughout using *Klebsiella pneumoniae* ATCC 700603 (ESBL-positive) and *Escherichia coli* ATCC 25922 (ESBL-negative).

Six of the twelve *E. coli* isolates were ESBL producers and the other six were susceptible to antibiotics.

## 2.2. Bacterial Extracts Isolations

Bacterial strains were fractionated into surface protein and DNA.

### 2.2.1. Surface Protein Isolation

Surface protein was isolated for each strain from 50 mL overnight liquid cultures (18 h) in duplicates, corresponding to the stationary growth phase. The method was adapted from previously published protocols, with slight modifications [21,22]. Cells were harvested by centrifugation (20 min, 10,000× *g*, 4 °C) and the resulting pellets were resuspended in 0.01 N NaOH solution. Protease inhibitors ethylenediaminetetraacetic acid (EDTA) and phenylmethylsulphonyl fluoride (PMSF) (Sigma-Aldrich, St. Louis, MO, USA) were added to all the solutions at final concentrations of 5 mM and 1 mM, respectively. Suspensions were gently agitated for 30 min at 37 °C in an orbital rotary agitator (Stuart SB3, Staffordshire, UK). After incubation and centrifugation, the supernatants containing the protein extracts were filtered (0.45 µm) and stored at –20 °C until further use. The protein concentration was measured using the Qubit™ Protein Assay Kit (Thermo Fisher Scientific, Waltham, MA, USA) prior to their use.

### 2.2.2. Bacterial DNA Isolation

DNA extraction was performed for each strain from 1.5 mL broth cultures using the GenElute™ Bacterial Genomic DNA Kit (Sigma-Aldrich, Dorset, UK) following the manufacturer's instructions. The DNA concentration was assessed using the Qubit™ DNA Assay Kit (Thermo Fisher Scientific, Waltham, MA, USA) and stored at –80 °C.

## 2.3. Peripheral Blood Mononuclear Cells (PBMC) Isolation and Stimulation with Bacterial Extracts

PBMC were isolated from 10 mL of peripheral blood obtained from healthy donors using a Ficoll-Histopaque gradient and cryopreserved in liquid nitrogen. Cell concentrations were adjusted to  $2 \times 10^6$  PBMC/mL in RPMI medium (Dominique Dutscher, Bernolsheim, France) supplemented with 5% fetal bovine serum (Biological Industries, Beit Haemek, Israel), 1% penicillin/streptomycin, and 1% glutamine (Biowest, Nuaille, France). This medium is hereafter referred to as complete-RPMI.

In preliminary experiments, we stimulated PBMC with surface protein extracts at concentrations of 0.02, 0.2, and 2 µg/mL in complete-RPMI medium in a final volume of 200 µL in 96-well culture plates (Thermo Fisher Scientific, Waltham, MA, USA). For DNA extracts, we tested concentrations of 0.2 and 2 µg/mL. PBMC in complete-RPMI alone served as the negative control. PBMC stimulated with lipopolysaccharide (LPS-EB ultrapure  $5 \times 10^6$  EU—InvivoGen, San Diego, CA, USA) at 1 µg/mL in complete-RPMI medium was used as the positive control. PBMC were incubated for 2 and 5 days at 37 °C.

For the final experiments we used surface protein extracts at 0.2 µg/mL and DNA extracts at 2 µg/mL because these concentrations performed best in preliminary tests. We incubated PBMC for two days because we aimed to assess the innate immune response rather than the adaptative response.

Because the yield of PBMC isolated from each healthy donor was insufficient to culture all 12 *E. coli* extracts we used extracts from *Escherichia coli* ATCC® 25922, a non-pathogenic clinical isolate from the American Type Culture Collection to standardize the results for all cultures.

#### 2.4. Determination of Cytokine Concentration and Ratio

Preliminary analysis of supernatants was conducted using a bead-based multiplex immunoassay ProcartaPlex™ Human Inflammation Panel, 20 plex (Thermo Fisher Scientific, Waltham, MA, USA). From among the 20 cytokines analyzed for the final experiments, we selected a battery of nine cytokines on the basis of their clinical relevance in patients with cirrhosis [2,12,13] and/or their role in innate immune response. This battery of cytokines captures key aspects of the immune response to microorganisms, encompassing pro-inflammatory, regulatory, and chemotactic functions, while limiting the number of analytes to ensure analytical robustness and comparability across samples. Specifically, we analyzed interferon-gamma (IFN-γ), IL-1β, IL-10, IL-12p70, monocyte chemoattractant protein-1 (MCP-1), IL-8/CXCL8, IL-6, macrophage inflammatory protein-1 (MIP-1α), and MIP-1β.

A ProcartaPlex™ Human MMP Panel, 5 plex (Thermo Fisher Scientific, Waltham, MA, USA) was used to measure interferon-gamma (IFN-γ), IL-1β, IL-10, IL-12p70, and monocyte chemoattractant protein-1 (MCP-1). We used specific ELISA kits for IL-8/CXCL8 (Mabtech, Nacka Strand, Sweden), IL-6 (ImmunoTools, Friesoythe, Germany), macrophage inflammatory protein (MIP)-1α and MIP-1β (PeproTech, Thermo Fisher Scientific, USA), because these cytokines were saturated in the ProcartaPlex™.

The lower limits of quantification were as follows: 11 pg/mL for IFN-γ, 2.76 pg/mL for IL-1β, 1.56 pg/mL for IL-10, 7.32 pg/mL for IL-12p70, 3.08 pg/mL for MCP-1, 4 pg/mL for IL-8, 6.1 pg/mL for IL-6 and 8 pg/mL for MIP-1α and MIP-1β. Supernatants were diluted 1/50 for IFN-γ, IL-1β, IL-10, IL-12p70 and MCP-1, 1/200 for IL-8 and IL-6, and 1/30 for MIP-1α and MIP-1β.

We normalized cytokine concentrations (in pg/mL) by calculating the ratio of cytokine production from pathogenic *E. coli* to that from standard *E. coli* ATCC® 25922 using the formula:

$$\text{ratio} = \frac{\text{Pathogenic } E. \text{ coli cytokine concentration} - \text{negative control cytokine concentration}}{\text{E. coli ATCC}^{\circledR} 25922 \text{ cytokine concentration} - \text{negative control cytokine concentration}}$$

We then compared the cytokine ratios between MDR and susceptible *E. coli*. We also compared the cytokine ratios between the different healthy donors and between the site of isolation of *E. coli* (ascitic fluid or blood).

#### 2.5. Statistical Analyses

Statistical analyses were conducted using Graph Pad Prism 9 software (GraphPad, Boston, MA, USA) and 2023 IBM SPSS Statistics for Windows, version 29.0.1.1 (IBM Corp., Armonk, NY, USA). The Shapiro–Wilk test was applied to test the normality of data distribution. Results are reported as percentages, median (IQR), and mean ± standard deviation. To test comparisons between groups we used the Fisher’s exact test, Mann–Whitney test, Student’s *t*-test, multivariable linear regression analysis, and the Bonferroni post-hoc test. Significance was established at a two-sided *p*-value lower than 0.05.

### 3. Results

Surface-associated protein extract and DNA extracts were obtained from multidrug-resistant *E. coli* (n = 6) and antibiotic-susceptible *E. coli* (n = 6) strains isolated from patients with cirrhosis, and from a reference *E. coli* strain (ATCC<sup>®</sup> 25922). *E. coli* extracts were used to stimulate in vitro PBMC from healthy donors (n = 8).

Table 1 shows the clinical characteristics of the patients from whom the *E. coli* were isolated. There were no statistically significant differences in clinical and analytical characteristics between the MDR *E. coli* group and the susceptible *E. coli* group. Both groups were predominantly men, with similar mean ages (69 ± 10 vs. 68 ± 13 years, respectively). The etiology of cirrhosis was mostly alcohol-related and metabolic dysfunction-associated steatotic liver disease (MASLD), with impaired liver function at the infection diagnosis: Child–Pugh scores of 9 and MELD 23 ± 5.1 vs. 20 ± 9.3, respectively. There was a non-significant trend to higher C-reactive protein levels and white blood cell count in patients infected by MDR *E. coli*. The MDR *E. coli* group had a non-significant higher proportion of previous antibiotic prophylaxis (66.7% vs. 33.3%). Bacteremia was more common in the MDR *E. coli* group, while SBP was more common in the susceptible *E. coli* group. Nosocomial infections were exclusively associated with MDR *E. coli*. Both groups had similar rates of acute kidney injury, cirrhosis decompensation, ACLF, and 30-day mortality.

**Table 1.** Clinical and analytical characteristics of patients with cirrhosis infected by MDR *E. coli* and antibiotic-susceptible *E. coli* from whom bacterial isolates were obtained. Results are expressed as percentages or mean ± standard deviation. Normality was assessed with the Shapiro–Wilk test; Student’s *t*-test or Mann–Whitney test were applied accordingly. Fisher’s exact test was used for comparisons of categorical variables. MASLD: metabolic dysfunction-associated steatotic liver disease; MetALD: metabolic and alcohol-related liver disease; MELD: model for end-stage liver disease; SBP: spontaneous bacterial peritonitis; HE: hepatic encephalopathy; ACLF: acute-on-chronic liver failure.

|   | Infection by<br>MDR <i>E. coli</i><br>n = 6 | Infection by<br>Susceptible <i>E. coli</i><br>n = 6 | <i>p</i> -Value |
|---|---|---|-----------------|
| Sex, M/F, n (%)                                   | 6 (100%)/0                                  | 4 (66.7%)/2 (33.3%)                                 | 0.45            |
| Age, (years)                                      | 69 ± 10                                     | 68 ± 13   | 0.48            |
| Etiology of cirrhosis, n (%)                      |   |   |                 |
| Alcohol-related liver disease                     | 2 (33.3%)                                   | 1 (16.7%)   | 0.46            |
| MASLD   | 3 (50%)                                     | 2 (33.3%)   |                 |
| MetALD  | 1 (16.7%)                                   | 1 (16.7%)   |                 |
| Alcohol + Autoimmune                              | 0   | 2 (33.3%)   |                 |
| Child–Pugh score at infection diagnosis, (points) | 9 ± 2.3                                     | 9 ± 1.7   | 0.50            |
| MELD score at infection diagnosis, (points)       | 23 ± 5.1                                    | 20 ± 9.3  | 0.23            |
| C-reactive protein (mg/dL)                        | 103.0 ± 63.4                                | 93.7 ± 50.0   | 0.78            |
| White blood cell count (×10 <sup>9</sup> /L)      | 10.9 ± 5.5                                  | 8.2 ± 4.4   | 0.38            |
| Antibiotic prophylaxis, n (%)                     | 4 (66.7%)                                   | 2 (33.3%)   | 0.57            |
| Type of infection, n (%)                          |   |   |                 |
| Bacteremia  | 4 (66.7%)                                   | 2 (33.3%)   | 0.56            |
| SBP   | 2 (33.3%)                                   | 4 (66.7%)   |                 |

Table 1. Cont.

|  | Infection by<br>MDR <i>E. coli</i><br>n = 6 | Infection by<br>Susceptible <i>E. coli</i><br>n = 6 | p-Value |
|--|---|---|---------|
| Site of acquisition, n (%)                           |   |   |         |
| Community-acquired                                   | 2 (33.3%)                                   | 3 (50%)   | 0.07    |
| Healthcare associated                                | 2 (33.3%)                                   | 3 (50%)   |         |
| Nosocomial   | 2 (33.3%)                                   | 0   |         |
| Acute kidney injury at infection<br>diagnosis, n (%) | 2 (33.3%)                                   | 3 (50%)   | 1       |
| Decompensation of cirrhosis, n (%)                   | 6 (100%), of which:                         | 5 (83.3%), of which:                                |         |
| Ascites  | 3 (50%)                                     | 5 (100%)  | 1       |
| Variceal bleeding                                    | 1 (16.7%)                                   | 0   |         |
| Ascites + HE   | 2 (33.3%)                                   | 0   |         |
| ACLF, n (%)  | 1 (16.7%)                                   | 2 (33.3%)   | 1       |
| 30-day mortality, n (%)                              | 1 (16.7%)                                   | 0   | 1       |

We compared the cytokine production between MDR *E. coli* and antibiotic-susceptible *E. coli* (Figure 1 and Table S1 and Table S2 in the Supplementary Materials). No statistically significant differences were detected in the production of any cytokine between MDR and susceptible strains.




Figure 1. Violin plots showing standardized ratio of cytokine production in response to *E. coli* surface protein extract (a) and DNA extract (b), according to bacterial antibiotic susceptibility (antibiotic-susceptible in green, MDR in blue). Data are presented as individual results and median with IQR. Normality was assessed with the Shapiro–Wilk test; Student’s *t*-test or Mann–Whitney test were applied accordingly. No statistically significant differences between susceptible and MDR strains were detected in the production of any cytokine.

Multivariable linear regression analysis confirmed this finding and revealed that the individual healthy donor significantly influenced the production of several cytokines (Table 2). Specifically, IL-1 $\beta$ , IL-10, IL-12p70, MCP-1, IL-8, MIP-1 $\alpha$ , and MIP-1 $\beta$  levels in cultures stimulated with surface protein extracts showed statistically significant differences among healthy donors. Similarly, the individual healthy donor was associated with different production of IFN- $\gamma$ , IL-1 $\beta$ , IL-10, IL-12p70, IL-8, IL-6, MIP-1 $\alpha$ , and MIP-1 $\beta$  in cultures stimulated with DNA extracts. No significant differences were observed among healthy donors for IFN- $\gamma$  and IL-6 levels in response to surface extracts, nor for MCP-1 levels in response to DNA extracts.

**Table 2.** Multivariable linear regression analysis for each cytokine. Coefficients indicate the magnitude of the difference between antibiotic-susceptible vs. MDR *E. coli*; results are expressed as  $\beta$  coefficient and 95% confidence intervals. *p*-values for antibiotic-susceptible vs. MDR *E. coli* and among healthy donors are reported.


|                |                      | Surface Protein Extract                       |                | DNA Extract                                   |                |
|----------------|----------------------|---|----------------|---|----------------|
|                |                      | Antibiotic-Susceptible vs. MDR <i>E. coli</i> | Healthy Donors | Antibiotic-Susceptible vs. MDR <i>E. coli</i> | Healthy Donors |
| IL-1 $\beta$   | coefficient (95% CI) | 1.01 (−3.51–5.53)                             | -              | 0.03 (−1.15–1.21)                             | -              |
|                | <i>p</i> -value      | 0.65  | <0.001 *       | 0.96  | <0.001 *       |
| IL-10          | coefficient (95% CI) | −0.19 (−3.84–3.47)                            | -              | −0.14 (−5.78–5.48)                            | -              |
|                | <i>p</i> -value      | 0.92  | 0.01 *         | 0.96  | 0.002 *        |
| IL-12p70       | coefficient (95% CI) | 0.39 (−2.28–3.05)                             | -              | 0.71 (−3.07–4.49)                             | -              |
|                | <i>p</i> -value      | 0.77  | <0.001 *       | 0.70  | 0.01 *         |
| IFN- $\gamma$  | coefficient (95% CI) | −0.07 (−4.61–4.47)                            | -              | −0.04 (−3.6–3.53)                             | -              |
|                | <i>p</i> -value      | 0.97  | 0.18           | 0.98  | 0.008 *        |
| MCP-1          | coefficient (95% CI) | 0.11 (−2.95–3.18)                             | -              | −0.42 (−4.32–3.48)                            | -              |
|                | <i>p</i> -value      | 0.94  | <0.001 *       | 0.83  | 0.40           |
| IL-6           | coefficient (95% CI) | 0.11 (−4.81–5.02)                             | -              | −0.18 (−1.40–1.05)                            | -              |
|                | <i>p</i> -value      | 0.96  | 0.93           | 0.77  | 0.045 *        |
| IL-8           | coefficient (95% CI) | 0.11 (−2.08–2.31)                             | -              | 0.06 (−2.36–2.50)                             | -              |
|                | <i>p</i> -value      | 0.92  | <0.001 *       | 0.96  | <0.001 *       |
| MIP-1 $\alpha$ | coefficient (95% CI) | 0.13 (−0.36–0.62)                             | -              | −0.13 (−1.10–0.84)                            | -              |
|                | <i>p</i> -value      | 0.58  | <0.001 *       | 0.78  | 0.01 *         |
| MIP-1 $\beta$  | coefficient (95% CI) | −0.04 (−2.19–2.11)                            | -              | 0.03 (−0.59–0.64)                             | -              |
|                | <i>p</i> -value      | 0.97  | 0.004 *        | 0.93  | 0.01 *         |

(\*): statistically significant *p*-values.

To further explore these findings, we generated volcano plots (Figures 2 and 3) to illustrate the coefficients and *p*-values with Bonferroni correction for cytokine production between susceptible and MDR strains and the variability among healthy donors. For example, in Figure 2, regarding IL-1 $\beta$ , donor J exhibited a different cytokine production pattern to that of the other donors. For IL-10, donor G showed the greatest difference. In contrast, no significant differences were observed among donors for IFN- $\gamma$ .


Among the cytokines analyzed, the production levels were highest for IL-1 $\beta$  in surface protein extracts (ratio of 1.70 (0.24–3.49) for MDR strains vs. 1.61 (0.48–3.98) for susceptible strains, *p* = 0.54) and for IL-10 and MCP-1 in DNA extracts (ratios of 0.50 (0.13–1.39) vs. 0.96 (0.47–2.16), *p* = 0.19, and 1.34 (0.78–2.37) vs. 0.88 (0.36–2.63), *p* = 0.44, respectively) (Figure 1 and Tables S1 and S2 in the Supplementary Materials).

Lastly, we studied whether the type of infection, and consequently the site of bacterial isolation, influenced the immune response. We observed no significant differences in cytokine production based on the source of infection (ascites vs. blood) (Figure 4 and Tables S3 and S4 in the Supplementary Materials).



**Figure 2.** Volcano plots showing cytokine production in response to *E. coli* surface protein extract. Coefficients indicate the magnitude of the difference between antibiotic-susceptible and MDR *E. coli* (indicated by an orange dot), and between each healthy donor and every other healthy donor individually (represented by a white circle, with each donor labeled by a capital letter). *p*-values using multivariable linear regression with Bonferroni correction for each coefficient are represented as  $-\log_{10}$ . A value of  $-\log_{10}$  higher than 1.3 corresponds to a *p*-value < 0.05 (red dot line) and indicates statistical significance.





**Figure 4.** Violin plots showing the standardized ratio of cytokine production in response to *E. coli* surface protein extract (a) and DNA extract (b), according to the site of infection (ascites vs. blood). Antibiotic-susceptible strains are represented by green dots and MDR strains by blue dots. Data are presented as individual results and median with IQR. Normality was assessed with the Shapiro–Wilk test, Student’s *t*-test, or Mann–Whitney test were applied accordingly. No statistically significant differences were detected between ascites and blood in the production of any cytokine.

#### 4. Discussion

The main finding in the present study was that the *in vitro* cytokine production by PBMC from healthy donors challenged with *E. coli* isolated from patients with cirrhosis was similar in MDR and susceptible strains. In addition, the production of most cytokines differed among individual healthy donors.

The rising prevalence of infections caused by MDRO worldwide is a serious threat to global public health, especially in patients with cirrhosis [6]. The link between MDR infections and higher mortality observed in previous reports [23,24] could have several non-exclusive explanations, such as delays in appropriate antibiotic treatment [6,9,11], intrinsic host factors [25], and bacterial virulence factors [26]. However, a different elicited immune response between MDR and susceptible bacteria could also contribute to the worse prognosis in the former. Few studies have evaluated *in vitro* how immunity responds to MDR *E. coli* through cytokine production. Bristianou et al. studied the early release of cytokines by human monocytes from healthy donors stimulated by *E. coli* obtained from the urine of women with acute pyelonephritis [14]. They observed a higher production of TNF, IL-6, and IL-8 by MDR *E. coli* than by susceptible strains, while the opposite occurred for IL-12. In contrast, Auger et al. found that beta-lactam-resistant *E. coli* strains isolated from urine or blood incubated with whole blood from healthy donors induced significantly lower levels of TNF- $\alpha$  and IL-1 $\beta$  than susceptible strains [15]. This discrepancy with Bristianou et al.’s results was attributed to the use of whole blood instead of monocytes.

In our study the battery of cytokines was selected on the basis of their clinical relevance in patients with cirrhosis [2,12,13] and/or their role in innate immune response to

microorganisms, the target of our experimental approach. This battery included IFN- $\gamma$ , IL-1 $\beta$ , IL-10, IL-12p70, MCP-1, MIP-1 $\alpha$ , MIP-1 $\beta$ , IL-6, and IL-8 and allowed us to analyze essential components of the immune response, covering pro-inflammatory, regulatory, and chemotactic functions. We did not find statistically significant differences in the production of any of these cytokines between MDR *E. coli* and susceptible strains. It is of note that the production of IL-6 and IL-8, pro-inflammatory cytokines with a relevant prognostic value in cirrhosis [12,13], did not differ between the two groups of *E. coli* strains. These results suggest that the worse prognosis of MDR *E. coli* infections is more likely attributable to factors such as delayed appropriate antibiotic treatment [6,9] or a patient's poorer baseline status than to a different immune response elicited by the bacteria. Moreover, our data in vitro do not support the use of specific immune modulation as a therapeutic strategy for sepsis caused by MDR *E. coli*. However, we cannot exclude the potential role of therapeutic immune modulation in vivo or in other contexts [27].

The mechanisms of antibiotic resistance in *E. coli* are mainly located in the bacterial envelope. These mechanisms include antibiotic inactivating/modifying enzymes (such as carbapenemases and ESBLs), outer membrane porin remodeling, enhanced efflux pump action to actively transport antibiotics out of the cell, and alteration of antibiotic target sites (e.g., lipid A region of lipopolysaccharide) [28]. In the present study, all the MDR *E. coli* were ESBL-producing strains. Therefore, it seemed interesting to study the differences between MDR and susceptible *E. coli* in the immune response elicited specifically by the surface bacterial extract. However, although the surface components of bacteria play a key role in triggering the human immune response, other bacterial components such as CpG DNA also stimulate this response. In effect, circulating bacterial DNA is associated with the proinflammatory state [29] and a worse prognosis [30] in patients with cirrhosis. Notably, bacterial surface and DNA components stimulate the immune system through different pathways. Surface lipopolysaccharide binds to Toll-like receptor (TLR) 4 and lipoproteins to TLR 2/TLR 1 whereas bacterial CpG-containing DNA binds to TLR 9 [31–34]. The immune response to surface components could therefore differ from that elicited by DNA extracts. For this reason, in contrast to the studies by Bristianou and Auger who used the whole bacteria [14,15], we analyzed the surface extract and the DNA extract separately, and we did not find relevant differences in the immune response between MDR *E. coli* and susceptible *E. coli* in any. However, whole bacteria may simultaneously activate multiple pattern recognition receptors, resulting in a synergistic cytokine regulation [35]. This effect could lead to an immune response different from that elicited by surface and DNA extracts separately. Future studies comparing whole bacteria with their isolated components could provide further insight into these interactions.

In this study, we used PBMC from healthy donors rather than from patients with cirrhosis to minimize variability and potential confounding factors. Patients with cirrhosis exhibit high heterogeneity in baseline immune alterations, history of infections, liver failure severity, comorbidities and pharmacological treatments. All these factors could mask potential differences in cytokine production between MDR and susceptible *E. coli*, especially given the limited number of strains analyzed. Therefore, we decided to use PBMC from healthy donors, a theoretically more homogeneous population. Nevertheless, among the healthy donors, we observed high variability in the production of most cytokines, highlighting the role of genetic polymorphisms and environmental factors in modulating inflammatory pathways. For instance, a genome-wide association study revealed innate immunity was strongly influenced by several genetic loci, while factors such as smoking, age, and sex were shown to predominantly influence adaptive immunity [36]. Previous microbial exposure may also influence systemic immune responses, including cytokine production. It is important to consider that patients with cirrhosis exhibit a different

immune response compared to healthy subjects. In fact, an exaggerated *in vitro* response to bacterial products has been reported in patients with cirrhosis compared to healthy controls, particularly in the production of interferons, IL-6 and IL-8 [37]. Therefore, it remains unknown whether the similar cytokine profile found between MDR and susceptible *E. coli* strains in PBMC from healthy controls can be extrapolable to PBMC from patients with cirrhosis.

The cytokines with the highest production were IL-1 $\beta$  in surface extracts and IL-10 and MCP-1 in DNA extracts. IL-1 $\beta$  is a proinflammatory cytokine that has an important role in the immune response after the initial host recognizes bacterial infection and enhances phagocyte recruitment and function [38]. MCP-1 is a chemokine that plays a key role in recruiting monocytes and polymorphonuclear cells [39]. In contrast, IL-10 has been reported to act as an anti-inflammatory cytokine that protects the host from a harmful uncontrolled immune response [38]. Nevertheless, IL-10 can also exhibit immunostimulatory properties under certain conditions [40].

The site from which *E. coli* was isolated (ascitic fluid vs. blood) did not significantly influence the *in vitro* immune response. This observation aligns with the understanding that SBP and spontaneous bacteremia—the most characteristic infections in cirrhosis—share the common pathophysiological pathway of bacterial translocation, with bacteria originating from the intestinal lumen moving to various extraintestinal sites [41].

Our study has certain limitations. First, the number of bacteria is limited. However, our intention was to mimic an *ex vivo* clinical scenario using strains isolated from infected patients with cirrhosis and to evaluate a comprehensive battery of cytokines. Second, we used multiple healthy donors instead of relying on a single donor for all experiments. The variability generated between these different donors could therefore limit the comparison between MDR and susceptible strains. However, we tried to control this potential bias by multivariable linear regression analysis. This approach of using several healthy donors increased the generalizability of our results and allowed us to observe the role of donor variability in the immune response. Third, the PBMC were obtained from healthy donors rather than patients with cirrhosis. Nonetheless, this serves as a preliminary approach to understanding how the general population responds to MDR *E. coli* and provides a foundation for future studies with PBMC from patients with cirrhosis. It would also be valuable to extend this approach to other MDR bacteria. Fourth, we used different cytokine quantification techniques to evaluate the results because some cytokines were saturated in the multiplex immunoassay. While this introduced variability, it allowed us to assess a broader range of cytokine responses. Lastly, our study is based on *in vitro* experiments. While valuable to understand certain aspects of immune responses under well-defined conditions, such experiments cannot fully replicate the complexity and dynamic nature of the immune environment *in vivo*.

## 5. Conclusions

Within the limitations of the sample size, we conclude that there were no significant differences in *in vitro* cytokine production between MDR and antibiotic-susceptible *E. coli* strains isolated from infected patients with cirrhosis. This result suggests that the poor prognosis associated with MDR infections is likely driven by factors other than differences in immune response. Furthermore, our data *in vitro* do not support the use of specific immune modulation as a targeted therapeutic approach for MDR infections. Notably, we observed that immune response was strongly influenced by interindividual variability among healthy donors. This result underscores the importance of considering host variability in shaping immune response to infections. Future research should explore

the underlying mechanisms of this variability and its clinical implications, particularly in vulnerable populations such as patients with cirrhosis.

**Supplementary Materials:** The following supporting information can be downloaded at: <https://www.mdpi.com/article/10.3390/microorganisms13051164/s1>, Table S1: Standardized ratio of cytokine production in response to *E. coli* surface protein extract (a) and DNA extract (b), according to bacterial antibiotic susceptibility. Results are expressed as median (IQR). Normality was assessed with the Shapiro–Wilk test; Student’s *t*-test or Mann–Whitney test were applied accordingly; Table S2: Absolute concentrations (pg/mL) of cytokine production in response to *E. coli* surface protein extract (a) and DNA extract (b), according to bacterial antibiotic susceptibility. Results are expressed as median (IQR). Normality was assessed with the Shapiro–Wilk test; Student’s *t*-test or Mann–Whitney test were applied accordingly; Table S3: Standardized ratio of cytokine production in response to *E. coli* surface protein extract (a) and DNA extract (b), according to the site of infection (ascites vs. blood). Results are expressed as median (IQR). Normality was assessed with the Shapiro–Wilk test; Student’s *t*-test or Mann–Whitney test were applied accordingly; Table S4: Absolute concentrations (pg/mL) of cytokine production in response to *E. coli* surface protein extract (a) and DNA extract (b), according to the site of infection (ascites vs. blood). Results are expressed as median (IQR). Normality was assessed with the Shapiro–Wilk test; Student’s *t*-test or Mann–Whitney test were applied accordingly.

**Author Contributions:** Conceptualization, B.C., E.C., S.V., and G.S.; methodology, B.C., E.C., S.V., and G.S.; patient selection, B.C., E.A.-T., E.R., M.P., M.À.E., and G.S.; bacteria isolation, E.M. and F.N.; experiments, B.C., E.C., and E.S.-A.; data analysis, B.C., E.C., S.V., A.F.-G., and G.S.; writing—original draft preparation, B.C.; writing—review and editing, B.C., E.C., E.A.-T., E.R., F.N., S.V., and G.S.; supervision, S.V. and G.S. All authors have read and agreed to the published version of the manuscript.

**Funding:** B.C. received a grant “Ajut per Iniciació a la Recerca” from the Societat Catalana de Digestologia to support this research. E.A.T. is a recipient of a Joan Rodes award from the ISCII (JR20/00047) and the PI21/01995 grant from the ISCIII-Fondos Feder.

**Institutional Review Board Statement:** The study was conducted in accordance with the Declaration of Helsinki, and approved by the Institutional Ethics Committee (Comitè d’Ètica d’Investigació amb Medicaments-CEIm) of Hospital de la Santa Creu i Sant Pau, Barcelona (protocol code IIBSP-RES-2018-91, approval date: 10 June 2020).

**Informed Consent Statement:** Informed consent was obtained from all subjects involved in the study.

**Data Availability Statement:** The original contributions presented in this study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.

**Acknowledgments:** The authors thank Carolyn Newey for the English language revision.

**Conflicts of Interest:** The authors declare no conflicts of interest.

## Abbreviations

The following abbreviations are used in this manuscript:

|               |   |
|---------------|---|
| ACLF          | Acute-on-chronic liver failure;                             |
| CAID          | Cirrhosis-associated immune dysfunction;                    |
| HE            | Hepatic encephalopathy;                                     |
| ESBL          | Extended-spectrum—betalactamases;                           |
| EUCAST        | European Committee on Antimicrobial Susceptibility Testing; |
| IFN- $\gamma$ | Interferon-gamma;   |
| MASLD         | Metabolic dysfunction-associated steatotic liver disease;   |
| MCP-1         | Monocyte chemoattractant protein-1;                         |

|        |  |
|--------|--|
| MDR    | Multidrug-resistant;                         |
| MDRO   | Multidrug-resistant organisms;               |
| MetALD | Metabolic and alcohol-related liver disease; |
| MIP    | Macrophage inflammatory protein;             |
| PBMC   | Peripheral blood mononuclear cells;          |
| SBP    | Spontaneous bacterial peritonitis;           |
| TLR    | Toll-like receptor.                          |

## References

- Naghavi, M.; Vollset, S.E.; Ikuta, K.S.; Swetschinski, L.R.; Gray, A.P.; Wool, E.E.; Robles Aguilar, G.; Mestrovic, T.; Smith, G.; Han, C.; et al. Global Burden of Bacterial Antimicrobial Resistance 1990–2021: A Systematic Analysis with Forecasts to 2050. *Lancet* **2024**, *404*, 1199–1226. [[CrossRef](#)] [[PubMed](#)]
- Albillos, A.; Martin-Mateos, R.; Van der Merwe, S.; Wiest, R.; Jalan, R.; Álvarez-Mon, M. Cirrhosis-Associated Immune Dysfunction. *Nat. Rev. Gastroenterol. Hepatol.* **2022**, *19*, 112–134. [[CrossRef](#)]
- Jalan, R.; Fernandez, J.; Wiest, R.; Schnabl, B.; Moreau, R.; Angeli, P.; Stadlbauer, V.; Gustot, T.; Bernardi, M.; Canton, R.; et al. Bacterial Infections in Cirrhosis: A Position Statement Based on the EASL Special Conference 2013. *J. Hepatol.* **2014**, *60*, 1310–1324. [[CrossRef](#)]
- Piano, S.; Bunchorntavakul, C.; Marciano, S.; Rajender Reddy, K. Infections in Cirrhosis. *Lancet Gastroenterol. Hepatol.* **2024**, *9*, 745–757. [[CrossRef](#)]
- Gallaher, C.E.; Shawcross, D.L. Management of Multidrug-Resistant Infections in Cirrhosis. *Semin. Liver. Dis.* **2022**, *42*, 173–187. [[CrossRef](#)]
- Piano, S.; Singh, V.; Caraceni, P.; Maiwall, R.; Alessandria, C.; Fernandez, J.; Soares, E.C.; Kim, D.J.; Kim, S.E.; Marino, M.; et al. Epidemiology and Effects of Bacterial Infections in Patients with Cirrhosis Worldwide. *Gastroenterology* **2019**, *156*, 1368–1380.e10. [[CrossRef](#)]
- Diekema, D.J.; Hsueh, P.R.; Mendes, R.E.; Pfaller, M.A.; Rolston, K.V.; Sader, H.S.; Jones, R.N. The Microbiology of Bloodstream Infection: 20-Year Trends from the SENTRY Antimicrobial Surveillance Program. *Antimicrob. Agents Chemother.* **2019**, *63*, e00355-19. [[CrossRef](#)]
- Fernández, J.; Acevedo, J.; Weist, R.; Gustot, T.; Amoros, A.; Deulofeu, C.; Reverter, E.; Martínez, J.; Saliba, F.; Jalan, R.; et al. Bacterial and Fungal Infections in Acute-on-Chronic Liver Failure: Prevalence, Characteristics and Impact on Prognosis. *Gut* **2018**, *67*, 1870–1880. [[CrossRef](#)]
- Fernández, J.; Prado, V.; Trebicka, J.; Amoros, A.; Gustot, T.; Wiest, R.; Deulofeu, C.; Garcia, E.; Acevedo, J.; Fuhrmann, V.; et al. Multidrug-Resistant Bacterial Infections in Patients with Decompensated Cirrhosis and with Acute-on-Chronic Liver Failure in Europe. *J. Hepatol.* **2019**, *70*, 398–411. [[CrossRef](#)]
- Moreau, R.; Jalan, R.; Gines, P.; Pavesi, M.; Angeli, P.; Cordoba, J.; Durand, F.; Gustot, T.; Saliba, F.; Domenicali, M.; et al. Acute-on-Chronic Liver Failure Is a Distinct Syndrome That Develops in Patients with Acute Decompensation of Cirrhosis. *Gastroenterology* **2013**, *144*, 1426–1437.e9. [[CrossRef](#)]
- Song, K.H.; Jeon, J.H.; Park, W.B.; Park, S.W.; Bin Kim, H.; Oh, M.D.; Lee, H.S.; Kim, N.J.; Choe, K.W. Clinical Outcomes of Spontaneous Bacterial Peritonitis Due to Extended-Spectrum Beta-Lactamase-Producing Escherichia Coli and Klebsiella Species: A Retrospective Matched Case-Control Study. *BMC Infect. Dis.* **2009**, *9*, 41. [[CrossRef](#)] [[PubMed](#)]
- Clària, J.; Stauber, R.E.; Coenraad, M.J.; Moreau, R.; Jalan, R.; Pavesi, M.; Amor, A.; Titos, E.; Alcaraz-Quiles, J.; Oettl, K.; et al. Systemic Inflammation in Decompensated Cirrhosis: Characterization and Role in Acute-on-Chronic Liver Failure. *Hepatology* **2016**, *64*, 1249–1264. [[CrossRef](#)] [[PubMed](#)]
- Juanola, A.; Ma, A.T.; de Wit, K.; Gananandan, K.; Roux, O.; Zaccherini, G.; Jiménez, C.; Tonon, M.; Solé, C.; Villaseca, C.; et al. Novel Prognostic Biomarkers in Decompensated Cirrhosis: A Systematic Review and Meta-Analysis. *Gut* **2024**, *73*, 156–165. [[CrossRef](#)] [[PubMed](#)]
- Bristianou, M.; Panagou, C.; Adamis, T.; Raftogiannis, M.; Antonopoulou, A.; Chrisofos, M.; Galani, I.; Kanellakopoulou, K.; Tsaganos, T.; Giamarellos-Bourboulis, E.J. The Impact of Multidrug Resistance on the Pathogenicity of Escherichia Coli: An Experimental Study. *Int. J. Antimicrob. Agents* **2008**, *31*, 216–223. [[CrossRef](#)]
- Auger, G.; Corvec, S.; Roquilly, A.; Segain, J.P.; Lepelletier, D.; Reynaud, A.; Asehnoune, K. Escherichia Coli-Induced Productions of pro-Inflammatory Cytokines Are Regulated by MAP Kinases and G-Protein but Not by Akt: Relationship with Phylogenetic Groups and Resistance Patterns. *Cytokine* **2011**, *56*, 290–297. [[CrossRef](#)]
- Angeli, P.; Bernardi, M.; Villanueva, C.; Francoz, C.; Mookerjee, R.P.; Trebicka, J.; Krag, A.; Laleman, W.; Gines, P. EASL Clinical Practice Guidelines for the Management of Patients with Decompensated Cirrhosis. *J. Hepatol.* **2018**, *69*, 406–460. [[CrossRef](#)]

17. European Committee on Antimicrobial Susceptibility Testing Tables for Interpretation of MICs and Zone Diameters 8.1. Available online: [https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST\\_files/Breakpoint\\_tables/v\\_8.1\\_Breakpoint\\_Tables.pdf](https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_8.1_Breakpoint_Tables.pdf) (accessed on 20 December 2018).
18. European Committee on Antimicrobial Susceptibility Testing Tables for Interpretation of MICs and Zone Diameters 9.0. Available online: [https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST\\_files/Breakpoint\\_tables/v\\_9.0\\_Breakpoint\\_Tables.pdf](https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_9.0_Breakpoint_Tables.pdf) (accessed on 10 December 2019).
19. European Committee on Antimicrobial Susceptibility Testing Tables for Interpretation of MICs and Zone Diameters 10.0. Available online: [https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST\\_files/Breakpoint\\_tables/v\\_10.0\\_Breakpoint\\_Tables.pdf](https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_10.0_Breakpoint_Tables.pdf) (accessed on 12 December 2020).
20. EUCAST Guidelines for Detection of Resistance Mechanisms and Specific Resistances of Clinical and/or Epidemiological Importance. Available online: [https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST\\_files/Resistance\\_mechanisms/EUCAST\\_detection\\_of\\_resistance\\_mechanisms\\_170711.pdf](https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Resistance_mechanisms/EUCAST_detection_of_resistance_mechanisms_170711.pdf) (accessed on 12 December 2020).
21. Sánchez, B.; Arias, S.; Chaignepain, S.; Denayrolles, M.; Schmitter, J.M.; Bressollier, P.; Urdaci, M.C. Identification of Surface Proteins Involved in the Adhesion of a Probiotic *Bacillus Cereus* Strain to Mucin and Fibronectin. *Microbiology* **2009**, *155*, 1708–1716. [[CrossRef](#)]
22. Hidalgo-Cantabrana, C.; Lucena-Prieto, M.R.; Moro-García, M.A.; Alonso-Arias, R.; Sánchez, B. Whole Fractions from Probiotic Bacteria Induce In Vitro Th17 Responses in Human Peripheral Blood Mononuclear Cells. *J. Funct. Foods* **2018**, *48*, 367–373. [[CrossRef](#)]
23. Tabah, A.; Koulenti, D.; Laupland, K.; Missel, B.; Valles, J.; Bruzzi de Carvalho, F.; Paiva, J.A.; Çakar, N.; Ma, X.; Eggimann, P.; et al. Characteristics and Determinants of Outcome of Hospital-Acquired Bloodstream Infections in Intensive Care Units: The EUROBACT International Cohort Study. *Intensive Care Med.* **2012**, *38*, 1930–1945. [[CrossRef](#)]
24. Martin-Loeches, I.; Torres, A.; Rinaudo, M.; Terraneo, S.; de Rosa, F.; Ramirez, P.; Diaz, E.; Fernández-Barat, L.; Li Bassi, G.L.; Ferrer, M. Resistance Patterns and Outcomes in Intensive Care Unit (ICU)-Acquired Pneumonia. Validation of European Centre for Disease Prevention and Control (ECDC) and the Centers for Disease Control and Prevention (CDC) Classification of Multidrug Resistant Organisms. *J. Infect.* **2015**, *70*, 213–222. [[CrossRef](#)]
25. Vardakas, K.Z.; Rafailidis, P.I.; Konstantelias, A.A.; Falagas, M.E. Predictors of Mortality in Patients with Infections Due to Multi-Drug Resistant Gram Negative Bacteria: The Study, the Patient, the Bug or the Drug? *J. Infect.* **2013**, *66*, 401–414. [[CrossRef](#)] [[PubMed](#)]
26. Recker, M.; Laabei, M.; Toleman, M.S.; Reuter, S.; Saunderson, R.B.; Blane, B.; Török, M.E.; Ouadi, K.; Stevens, E.; Yokoyama, M.; et al. Clonal Differences in *Staphylococcus Aureus* Bacteraemia-Associated Mortality. *Nat. Microbiol.* **2017**, *2*, 1381–1388. [[CrossRef](#)] [[PubMed](#)]
27. Jacob, S.; Jacob, S.A.; Thoppil, J. Targeting Sepsis through Inflammation and Oxidative Metabolism. *World J. Crit. Care Med.* **2025**, *14*, 101499. [[CrossRef](#)]
28. Gauba, A.; Rahman, K.M. Evaluation of Antibiotic Resistance Mechanisms in Gram-Negative Bacteria. *Antibiotics* **2023**, *12*, 1590. [[CrossRef](#)]
29. Francés, R.; Zapater, P.; González-Navajas, J.M.; Muñoz, C.; Caño, R.; Moreu, R.; Pascual, S.; Bellot, P.; Pérez-Mateo, M.; Such, J. Bacterial DNA in Patients with Cirrhosis and Noninfected Ascites Mimics the Soluble Immune Response Established in Patients with Spontaneous Bacterial Peritonitis. *Hepatology* **2008**, *47*, 978–985. [[CrossRef](#)]
30. Zapater, P.; Francés, R.; González-Navajas, J.M.; de la Hoz, M.A.; Moreu, R.; Pascual, S.; Monfort, D.; Montoliu, S.; Vila, C.; Escudero, A.; et al. Serum and Ascitic Fluid Bacterial DNA: A New Independent Prognostic Factor in Noninfected Patients with Cirrhosis. *Hepatology* **2008**, *48*, 1924–1931. [[CrossRef](#)]
31. Frasinariu, O.E.; Ceccarelli, S.; Alisi, A.; Moraru, E.; Nobili, V. Gut-Liver Axis and Fibrosis in Nonalcoholic Fatty Liver Disease: An Input for Novel Therapies. *Dig. Liver Dis.* **2013**, *45*, 543–551. [[CrossRef](#)]
32. Hemmi, H.; Takeuchi, O.; Kawai, T.; Kaisho, T.; Sato, S.; Sanjo, H.; Matsumoto, M.; Hoshino, K.; Wagner, H.; Takeda, K.; et al. A Toll-like Receptor Recognizes Bacterial DNA. *Nature* **2000**, *408*, 740–745. [[CrossRef](#)]
33. Spohn, R.; Buwitt-Beckmann, U.; Brock, R.; Jung, G.; Ulmer, A.J.; Wiesmüller, K.-H. Synthetic Lipopeptide Adjuvants and Toll-like Receptor 2—Structure–Activity Relationships. *Vaccine* **2004**, *22*, 2494–2499. [[CrossRef](#)]
34. Matsuura, M. Structural Modifications of Bacterial Lipopolysaccharide That Facilitate Gram-Negative Bacteria Evasion of Host Innate Immunity. *Front. Immunol.* **2013**, *4*, 109. [[CrossRef](#)]
35. Oviedo-Boyso, J.; Bravo-Patiño, A.; Baizabal-Aguirre, V.M. Collaborative Action of Toll-Like and Nod-Like Receptors as Modulators of the Inflammatory Response to Pathogenic Bacteria. *Mediators Inflamm.* **2014**, *2014*, 432785. [[CrossRef](#)] [[PubMed](#)]
36. Patin, E.; Hasan, M.; Bergstedt, J.; Rouilly, V.; Libri, V.; Urrutia, A.; Alanio, C.; Scepanovic, P.; Hammer, C.; Jönsson, F.; et al. Natural Variation in the Parameters of Innate Immune Cells Is Preferentially Driven by Genetic Factors. *Nat. Immunol.* **2018**, *19*, 302–314. [[CrossRef](#)] [[PubMed](#)]

37. Kronsten, V.T.; Woodhouse, C.A.; Zamalloa, A.; Lim, T.Y.; Edwards, L.A.; Martinez-Llordella, M.; Sanchez-Fueyo, A.; Shawcross, D.L. Exaggerated Inflammatory Response to Bacterial Products in Decompensated Cirrhotic Patients Is Orchestrated by Interferons IL-6 and IL-8. *Am. J. Physiol. Gastrointest. Liver Physiol.* **2022**, *322*, G489–G499. [[CrossRef](#)] [[PubMed](#)]
38. Arango Duque, G.; Descoteaux, A. Macrophage Cytokines: Involvement in Immunity and Infectious Diseases. *Front. Immunol.* **2014**, *5*, 491. [[CrossRef](#)]
39. Deshmane, S.L.; Kremlev, S.; Amini, S.; Sawaya, B.E. Monocyte Chemoattractant Protein-1 (MCP-1): An Overview. *J. Interferon. Cytokine Res.* **2009**, *29*, 313–326. [[CrossRef](#)]
40. Carlini, V.; Noonan, D.M.; Abdalalem, E.; Goletti, D.; Sansone, C.; Calabrone, L.; Albini, A. The Multifaceted Nature of IL-10: Regulation, Role in Immunological Homeostasis and Its Relevance to Cancer, COVID-19 and Post-COVID Conditions. *Front. Immunol.* **2023**, *14*, 1161067. [[CrossRef](#)]
41. Guarner, C.; Soriano, G. Bacterial Translocation and Its Consequences in Patients with Cirrhosis. *Eur. J. Gastroenterol. Hepatol.* **2005**, *17*, 27–31. [[CrossRef](#)]

**Disclaimer/Publisher’s Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.